Clinical Trials Directory

Trials / Completed

CompletedNCT05523791

Whey Protein Supplementation in Patients With Parkinson's Disease

Can we Add Whey Protein Supplementation in Patients With Parkinson's Disease Without Interfering With Levodopa Response?

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
51 (actual)
Sponsor
Ospedale Generale Di Zona Moriggia-Pelascini · Academic / Other
Sex
All
Age
60 Years
Healthy volunteers
Not accepted

Summary

Many dietary supplementations are available to help people in balancing the protein intake and overcoming muscle mass loss. However, most of the products contain protein and could potentially affect levodopa action in people with Parkinson's disease (PWPD). The study aims at verify if whey protein supplementation interferes with dopamine replacement therapy efficacy in PWPD admitted at the clinic for a four weeks intensive multidisciplinary rehabilitation training.

Detailed description

Authors performed a randomised single blind monocentric study on PWPD admitted in the rehabilitative unit of the Moriggia Pelascini Hospital for a 4-week multidisciplinary intensive aerobic rehabilitation treatment. All patients received a standard protein redistribution dietary regimen plus a whey protein-based oral formula (N=26) or Magnesium (N=25) twice daily for 28 days. Neurological assessment and physical evaluation were conducted before (T0) and after (T1) rehabilitative treatment; dopamine replacement therapy was recorded T0 and T1 as well. The delta of changes within groups in neurological (UPDRS III) and physical (TUG, 6MW) evaluation scales was compared between groups.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTFortiralTwice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
DIETARY_SUPPLEMENTMg++Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water

Timeline

Start date
2022-01-01
Primary completion
2022-06-30
Completion
2022-06-30
First posted
2022-08-31
Last updated
2022-08-31

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05523791. Inclusion in this directory is not an endorsement.